Does lipoprotein(a) promote atherosclerosis and thrombosis by carrying oxidized phospholipids and inhibiting fibrinolysis?

Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle that is now recognized as a causal, independent risk factor for cardiovascular disease. Unlike standard LDL-C, Lp(a) possesses a unique protein component, apolipoprotein(a), which drives its pathogenicity through dual mechanisms of chronic inflammation and impaired clot breakdown.

Atherogenic and Pro-inflammatory Mechanisms

Lp(a) acts as the primary vehicle for oxidized phospholipids (OxPL) in the blood, sequestering approximately 80% to 90% of circulating OxPL. These phospholipids are highly bioactive and function as "danger signals" within the arterial wall.

• Molecular Pathways: OxPLs on the Lp(a) particle activate Toll-like receptor 2 (TLR2) and CD36 on monocytes and endothelial cells.
• Vascular Inflammation: This activation triggers the release of pro-inflammatory cytokines (IL-6, IL-8, and IL-1β), which accelerates monocyte recruitment and foam cell formation, leading to rapid plaque progression.

Thrombotic and Antifibrinolytic Effects

The apolipoprotein(a) component of Lp(a) shares 80% to 90% structural homology with plasminogen, the precursor to the primary clot-dissolving enzyme, plasmin.

• Competitive Inhibition: Because of this similarity, Lp(a) competes with plasminogen for binding sites on fibrin surfaces, particularly via its Kringle IV-10 domains.
• Clot Stability: By displacing plasminogen and inhibiting its activation by tissue plasminogen activator (tPA), Lp(a) effectively stalls the fibrinolysis process. This results in the formation of denser fibrin networks that are resistant to degradation, increasing the risk of stable, obstructive clots.

Clinical Implications

Genetic studies and Mendelian randomization have confirmed that elevated Lp(a) levels—typically defined as exceeding 30–50 mg/dL—significantly increase the risk of myocardial infarction, ischemic stroke, and calcific aortic valve stenosis. Because these levels are largely determined by inheritance rather than diet or lifestyle, Lp(a) represents a critical target for emerging antisense and siRNA therapies designed to lower cardiovascular risk beyond what is achievable with statins.

Bottom line

Lp(a) promotes cardiovascular disease through a "triple threat" mechanism: LDL-like cholesterol deposition, OxPL-driven arterial inflammation, and the competitive inhibition of fibrinolysis, making it a potent driver of both atherosclerosis and thrombosis.